Physician profile
Patrick J Hines
NPI 1023549821
$676.89
in general payments reported to CMS, 2019-2025
12 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.00 · 2020: $153 · 2022: $30.13 · 2024: $109 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $140.54 | 2020-2025 | Zepbound, Mounjaro |
| Agios Pharmaceuticals, INC. | $108.78 | 2024 | |
| Amgen INC. | $102.78 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $75.63 | 2025 | |
| Abbvie INC. | $59.30 | 2022-2025 | |
| Axsome Therapeutics, INC. | $51.70 | 2025 | Auvelity |
| Novo Nordisk INC | $50.25 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $22.05 | 2019 | |
| Esperion Therapeutics, INC. | $20.15 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $18.26 | 2020 | |
| Sumitomo Pharma America, INC. | $15.48 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.